Allison W. Kurian, M.D., M.Sc.

Publications

• Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Kurian AW, Lichtensztajn DY, Keegan TH, Leung RW, Shema SJ, Hershman DL, Kushi LH, Habel LA, Kolevska T, Caan BJ, Gomez SL. Breast Cancer Res Treat. 2013; 137 (1): 247-60
• Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research. Weber SC, Seto T, Olson C, Kenkare P, Kurian AW, Das AK. AMIA Annu Symp Proc. 2012: 2012 970-8
• Online tool to guide decisions for BRCA1/2 mutation carriers. Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK. J Clin Oncol. 2012; 30 (5): 497-506
• Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry. Kurian AW, Gong GD, John EM, Johnston DA, Felberg A, West DW, Miron A, Andrulis IL, Hopper JL, Knight JA, Ozcelik H, Dite GS, Apicella C, Southey MC, Whittemore AS. J Clin Oncol. 2011; 29 (34): 4505-9
• Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Kurian AW, Fish K, Shema SJ, Clarke CA. Breast Cancer Res. 2010; 12 (6): R99
• Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Kurian AW, Sigal BM, Plevritis SK. J Clin Oncol. 2010; 28 (2): 222-31
• Second primary breast cancer occurrence according to hormone receptor status. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. J Natl Cancer Inst. 2009; 101 (15): 1058-65
• Performance of BRCA1/2 mutation prediction models in Asian Americans. Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, Kingham KE, Crawford BB, Lee R, Chan S, Donlon SS, Ridge Y, Panabaker K, West DW, Whittemore AS, Ford JM. J Clin Oncol. 2008; 26 (29): 4752-8
• A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. J Clin Oncol. 2007; 25 (6): 634-41
• Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. JAMA. 2006; 295 (20): 2374-84
• Histologic types of epithelial ovarian cancer: have they different risk factors? Kurian AW, Balise RR, McGuire V, Whittemore AS. Gynecol Oncol. 2005; 96 (2): 520-30
• A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. de Bruin MA, Ford JM, Kurian AW. J Natl Compr Canc Netw. 2013; 11 (5): 512-7
• Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW. Fam Cancer. 2013; 12 (1): 65-73
• Information technology interventions to improve cancer care: a report from the American Society of Clinical Oncology Quality Care Symposium Kurian AW, Edge SB. J Oncol Pract. 2013; 9 (3): 142-144
• A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Sigal BM, Munoz DF, Kurian AW, Plevritis SK. Cancer Epidemiol Biomarkers Prev. 2012; 21 (7): 1066-77
• Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. Kwong A, Wong CH, Suen DT, Co M, Kurian AW, West DW, Ford JM. World J Surg. 2012; 36 (4): 702-13
• Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, Lacey JV. J Natl Cancer Inst. 2012; 104 (14): 1094-101
• Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, Sharma B, Kardashian A, Schackmann E, Kingham KE, Mills MA, West DW, Ford JM, Kurian AW. Fam Cancer. 2012; 11 (3): 429-39
• Genetic Polymorphisms as Predictors of Breast Cancer Risk de Bruin MA, Ford JM, Kurian AW. Curr Breast Cancer Rep. 2012: DOI 10.1007/s12609-0
• Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES. PLoS One. 2012; 7 (9): e43994
• In reply to Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: More Trouble With Phenocopies by Evans et al Kurian AW, Whittemore AS. J Clin Oncol. 2012: 30 1143-1144
• Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. Kwong A, Ng EK, Law FB, Wong HN, Wa A, Wong CL, Kurian AW, West DW, Ford JM, Ma ES. Breast Cancer Res Treat. 2012; 136 (3): 931-3
• Occurrence of breast cancer subtypes in adolescent and young adult women. Keegan TH, DeRouen MC, Press DJ, Kurian AW, Clarke CA. Breast Cancer Res. 2012; 14 (2): R55
• Patient, hospital, and neighborhood factors associated with treatment of early-stage breast cancer among Asian American women in California. Gomez SL, Press DJ, Lichtensztajn D, Keegan TH, Shema SJ, Le GM, Kurian AW. Cancer Epidemiol Biomarkers Prev. 2012; 21 (5): 821-34
• Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS. PLoS One. 2012; 7 (5): e33788
• A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Chen Y, Kingham K, Ford JM, Rosing J, Van Dam J, Jeffrey RB, Longacre TA, Chun N, Kurian A, Norton JA. Ann Surg Oncol. 2011; 18 (9): 2594-8
• Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D, Ford JM, Gomez SL. Breast Cancer Res Treat. 2011; 127 (2): 471-8
• Hereditary cancer: counseling women at risk Lebensohn A, Kingham K, Chun NM, Kurian AW. Contemporary OB/Gyn. 2011; 56 (4): 30-38
• BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Kurian AW, Curr Opin Obstet Gynecol. 2010; 22 (1): 72-8
• Genetic/familial high-risk assessment: breast and ovarian. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN. J Natl Compr Canc Netw. 2010; 8 (5): 562-94
• High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients. Kwong A, Ng EK, Law FB, Wong LP, To MY, Cheung MT, Wong HN, Chan VW, Kurian A, West DW, Ford JM, Ma ES. Breast Cancer Res Treat. 2010; 122 (2): 605-7
• Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. Gomez SL, Lichtensztajn D, Kurian AW, Telli ML, Chang ET, Keegan TH, Glaser SL, Clarke CA. J Clin Oncol. 2010; 28 (10): e155-7; author reply e158
• In reply to “Tailoring BRCRAPRO to Asian Americans” by S. Chen et al Kurian AW, Whittemore AS, Ford JM. Journal of Clinical Oncology. 2009: 27 643-4
• Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Kurian AW, Gong GD, John EM, Miron A, Felberg A, Phipps AI, West DW, Whittemore AS. Cancer Epidemiol Biomarkers Prev. 2009; 18 (4): 1084-91
• Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease. Vinayak S, Kurian AW. Curr Breast Cancer Rep. 2009; 1 (3): 148-156
• The decline in breast cancer incidence: real or imaginary? Kurian AW, Clarke CA, Carlson RW. Curr Oncol Rep. 2009; 11 (1): 21-8
• Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytology. Kurian AW, Hartman AR, Mills MA, Logan LJ, Sawyer AM, Ford JM, Daniel BL. Breast J. 2008 Mar-Apr; 14 (2): 211-4
• Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM. Fam Cancer. 2008; 7 (2): 179-86
• Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. Ghanouni P, Kurian AW, Margolis D, Hartman AR, Mills MA, Plevritis SK, Ford JM, Daniel BL. Breast J. 2007 May-Jun; 13 (3): 281-6
• A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Ghataorhe P, Kurian AW, Pickart A, Trapane P, Norton JA, Kingham K, Ford JM. Cancer Genet Cytogenet. 2007; 179 (2): 89-92
• CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM. Ann Surg. 2007; 245 (6): 873-9
• Biomedical terahertz imaging with a quantum laser cascade Kim SM, Hatami F, Harris JS, Kurian AW, Ford J, King D, Scalari G, Giovannini M, Hoyler N, Faist J, Harris G. Applied Physics Letters. 2006: 88 153903
• Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, Ford JM, Hartman AR. Cancer Epidemiol Biomarkers Prev. 2005; 14 (5): 1082-9
• Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Kurian AW, Hartman AR, Mills MA, Ford JM, Daniel BL, Plevritis SK. Health Expect. 2005; 8 (3): 221-33
• Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Hartman AR, Daniel BL, Kurian AW, Mills MA, Nowels KW, Dirbas FM, Kingham KE, Chun NM, Herfkens RJ, Ford JM, Plevritis SK. Cancer. 2004; 100 (3): 479-89